Search
for

    Sort by

    Research 31–60 of 38

    1. Severe Lichen Planus Pigmentosus Inversus in an Elderly Female Following Intra-Articular Injections of Homeopathic Substances Dermato · 2026
    2. Cold Atmospheric Plasma for Breast Cancer Preprints.org · 2026
    3. Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System Pharmaceuticals · 2026
    4. Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System Preprints.org · 2026
    5. Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology Clinical & Translational Oncology · 2026
    6. Cancer-Related Alopecia Risk and Treatment Current Treatment Options in Oncology · 2025
    7. Breast cancer in a transgender man CA A Cancer Journal for Clinicians · 2025
    8. Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention Current Oncology · 2024
    9. Effect of adenosine triphosphate on ribociclib-induced skin toxicity in rats Cutaneous and Ocular Toxicology · 2023
    10. Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis Journal of Advanced Research · 2024 · 8 citations
    11. Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm Asia-Pacific Journal of Clinical Oncology · 2018 · 4 citations
    12. Safety assessment of cyclin-dependent kinase 4/6 inhibitors and comparison of time to adverse events PLoS ONE · 2025 · 2 citations
    13. Alopecia induced by CDK 4/6 Inhibitors and its Impact on the Quality of Life of Patients with advanced Breast cancer 2025
    14. Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report Curēus · 2024
    15. Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis Expert Review of Anticancer Therapy · 2017 · 28 citations
    16. Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database Frontiers in Pharmacology · 2025 · 2 citations
    17. Cancer Treatments and Alopecia: A Systematic Review Turkiye Klinikleri Journal of Internal Medicine · 2021 · 2 citations
    18. Real-World Safety Profile of Generic Palbociclib in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Prospective Observational Study in Iraq” Journal of cancer research updates · 2026
    19. Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need! American Journal of Clinical Dermatology · 2026
    20. The pharmacovigilance analysis of adverse events of erlotinib based on the open access FAERS database MedBA Medicine · 2026
    21. Real-world pharmacovigilance insights into drug-induced risk of alopecia Frontiers in Pharmacology · 2025
    22. Kalya Research: Complementary and Alternative Medicine (CAM) Virtual Research Assistant from Biomedical Literature 2023
    23. Hair Changes due to Drugs Elsevier eBooks · 2018
    24. Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China BMC Cancer · 2025 · 1 citations
    25. Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment Patient Preference and Adherence · 2021 · 12 citations
    26. Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study. Journal of Clinical Oncology · 2024
    27. Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review Pharmacological Reviews · 2022 · 49 citations
    28. NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders Journal of Medicinal Chemistry · 2025 · 45 citations
    29. PROTACs: A novel strategy for cancer drug discovery and development MedComm · 2023 · 44 citations
    30. Poster Presentations Australasian Journal of Dermatology · 2021 · 25 citations